<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80246</article-id><article-id pub-id-type="doi">10.7554/eLife.80246</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Antibiotic-induced accumulation of lipid II synergizes with antimicrobial fatty acids to eradicate bacterial populations</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-281038"><name><surname>Sidders</surname><given-names>Ashelyn E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8700-261X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280737"><name><surname>Kedziora</surname><given-names>Katarzyna M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308660"><name><surname>Arts</surname><given-names>Melina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308661"><name><surname>Daniel</surname><given-names>Jan-Martin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-308659"><name><surname>de Benedetti</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281039"><name><surname>Beam</surname><given-names>Jenna E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281040"><name><surname>Bui</surname><given-names>Duyen T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281041"><name><surname>Parsons</surname><given-names>Joshua B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-199798"><name><surname>Schneider</surname><given-names>Tanja</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7269-4716</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279134"><name><surname>Rowe</surname><given-names>Sarah E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8955-359X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-279640"><name><surname>Conlon</surname><given-names>Brian P</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2155-8375</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Department of Microbiology and Immunology</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Genetics</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Institute for Pharmaceutical Microbiology</institution>, <institution>University of Bonn</institution>, <addr-line><named-content content-type="city">Bonn</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-63858"><name><surname>Helaine</surname><given-names>Sophie</given-names></name><role>Reviewing editor</role><aff><institution>Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bconlon@med.unc.edu</email> (BC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e80246</elocation-id><history><date date-type="received"><day>13</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>05</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Sidders et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Sidders et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80246-v1.pdf"/><abstract><p>Antibiotic tolerance and antibiotic resistance are the two major obstacles to the efficient and reliable treatment of bacterial infections. Identifying antibiotic adjuvants that sensitize resistant and tolerant bacteria to antibiotic killing may lead to the development of superior treatments with improved outcomes. Vancomycin, a lipid II inhibitor, is a frontline antibiotic for treating methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and other Gram-positive bacterial infections. However, vancomycin use has led to the increasing prevalence of bacterial strains with reduced susceptibility to vancomycin. Here we show that unsaturated fatty acids (UFAs) act as potent vancomycin adjuvants to rapidly kill a range of Gram-positive bacteria, including vancomycin-tolerant and resistant populations. The synergistic bactericidal activity relies on the accumulation of membrane-bound cell wall intermediates that generate large fluid patches in the membrane leading to protein delocalization, aberrant septal formation, and loss of membrane integrity. Our findings provide a natural therapeutic option that enhances vancomycin activity against difficult-to-treat pathogens and the underlying mechanism may be further exploited to develop antimicrobials that target recalcitrant infection.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI137273</award-id><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Conlon</surname><given-names>Brian P</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Schneider</surname><given-names>Tanja</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Sarah E Rowe, is co-inventor on a provisional patent (WO2019018594A1) describing the use of membrane acting agents for potentiating antibiotic efficacy.</p></fn><fn fn-type="conflict" id="conf3"><p>Brian P Conlon, is co-inventor on a provisional patent (WO2019018594A1) describing the use of membrane acting agents for potentiating antibiotic efficacy.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The raw numerical data for figures 1, 2, 3, 5, and 8 are provided in Source Data files for each figure.The full analysis code for Figure 4 is available on Github while all raw imaging data and key processed steps were deposited in Zenodo repository</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Sidders AE</collab><collab>Kedziora KM</collab><collab>Beam JE</collab><collab>Bui DT</collab><collab>Parsons J</collab><collab>Rowe SE</collab><collab>Conlon BP</collab></person-group><year iso-8601-date="2022">2022</year><source>Antibiotic-induced accumulation of lipid II sensitizes bacteria to antimicrobial fatty acids.</source><ext-link ext-link-type="uri" xlink:href="https://github.com/fjorka/bacteria_pa_van_analysis">https://github.com/fjorka/bacteria_pa_van_analysis</ext-link><comment>GitHub</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-80246-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>